Abstract
Microbes are the dominating organism on earth; they have impacted the life of animals as well as on humans during the course of evolution. Humans have encounter with plethora of microbes in several ways. Consequently, microbes get familiarized themselves with a new host (human) and further shared their residence with the most complex and intelligent organism on earth. The desire of humans for a civilized life them on a battlefield. Herein, the complex and brainy organisms were defeated by tiny creatures many times. During this phase microbes acquired several traits which helped them in conquering the battle with humans, and adversely affacted thier life. After the incorporation of techniques, micrbial world could explored. Sophisticated instruments have revealed fine aspects of microbes and get familiarized that they as bad as good. There are sever epidemic and pandemics have been reported those threateded the humanity. Ancient medical history is an evidence of deadly pathogens and failure of controlling strategies. However, the modern era of antibiotic brought some hope for disease-free civilized life on this planet. In this chapter, the details of twenty-first-century antibiotics have been discussed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abraham EP, Chain E (1940) An enzyme from bacteria able to destroy penicillin. Nature 146(3713):837
Burnet M, Burnet FM, White DO (1972) Natural history of infectious disease. CUP Archive
Cullinan M, Clarke M, Dallman T, Peart S, Wilson D, Weiand D (2017) Salmonella Typhimurium gastroenteritis leading to chronic prosthetic vascular graft infection. JMM Case Rep 4(8):e005104
Dawson R, Harris K, Conradie A, Burger D, Murray S, Mendel C, Spigelman M (2017) Efficacy of bedaquiline, pretomanid, moxifloxacin & PZA (BPAMZ) against DS-& MDR-TB. In: Conference on retroviruses and opportunistic infections [proceedings on the internet], pp 13–16
Donadio S, Maffioli S, Monciardini P, Sosio M, Jabes D (2010) Antibiotic discovery in the twenty-first century: current trends and future perspectives. J Antibiot 63(8):423
Eckburg P (2009) Focus 1 and 2: randomized double-blinded, multicenter phase III trials of the efficacy and safety of ceftaroline (CPT) vs ceftriaxone (CRO) in community-acquired pneumonia (CAP). In: Abstracts of papers of 49th Intersci Conf on Antimicrob Agents Chemother, San Francisco, 2009
European Centre for Disease Prevention and Control (2008) Annual epidemiological report on communicable diseases, 2008. European Centre for Disease Prevention of Control, Stockholm
FDA, DRAFT GUIDANCE (2017 January) Medical product communications that are consistent with the Food and Drug Administration-required Labeling—questions and answers, https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm537130.pdf
Fernandes P, Martens E, Bertrand D, Pereira D (2016) The solithromycin journey—it is all in the chemistry. Bioorg Med Chem. https://doi.org/10.1016/j.bmc.2016.08.035
Garcia-Salguero C, Rodriguez-Avial I, Picazo JJ, Culebras E (2015) Can plazomicin alone or in combination be a therapeutic option against carbapenem-resistant Acinetobacter baumannii? Antimicrob Agents Chemother 59(10). (2015)):5959–5966
Gibbons RJ (1964) The source of salivary bacteria. Arch Oral Biol 9:101–103
Gonzalez-Escobedo G, Marshall JM, Gunn JS (2011) Chronic and acute infection of the gall bladder by Salmonella Typhi: understanding the carrier state. Nat Rev Microbiol 9(1):9
Gottlieb S, Food, U.S (2018) Statement from FDA Commissioner Scott Gottlieb. In: MD on new steps to improve FDA review of shared risk evaluation and mitigation strategies to improve generic drug access. US Food and Drug Administration. [Online]. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm584259.htm. p 14
Hunter PR (2003) Climate change and waterborne and vector-borne disease. J Appl Microbiol 94:37–46
Kepplinger EE (2015) FDA’s expedited approval mechanisms for new drug products. Biotechnol Law Rep 34(1):15–37
Kirby WM (1944) Extraction of a highly potent penicillin inactivator from penicillin resistant staphylococci. Science 99(2579):452–453
Lapuebla A, Abdallah M, Olafisoye O, Cortes C, Urban C, Landman D, Quale J (2015) Activity of imipenem with relebactam against gram-negative pathogens from New York City. Antimicrob Agents Chemother 59(8):5029–5031. https://doi.org/10.1128/AAC.00830-15
Low M (2017) The tuberculosis treatment pipeline: a breakthrough year for the treatment of XDR-TB. PIPELINE REPORT. p 129
Mack A, Choffnes ER, Hamburg MA, Relman DA (eds) (2009) Microbial evolution and co-adaptation: a tribute to the life and scientific legacies of Joshua Lederberg: workshop summary. National Academies Press
Nelson K et al (2017) Whole-genome sequencing and spatial analysis of XDR-TB transmission in South Africa. Conference on Retroviruses and Opportunistic Infections (CROI 2017), Seattle, abstract 77
Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS (2008) A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 46(5):647–655
O’Gara JP (2017) Into the storm: chasing the opportunistic pathogen Staphylococcus aureus from skin colonisation to life-threatening infections. Environ Microbiol 19(10):3823–3833
Patz JA, Graczyk TK, Geller N, Vittor AY (2000) Effects of environmental change on emerging parasitic diseases. Int J Parasitol 30(12–13):1395–1405
Ryan F (1992) The forgotten plague: how the battle against tuberculosis was won – and lost. Little, Brown, p 323
Saxton K, Baines SD, Freeman J, O’Connor R, Wilcox MH (2009) Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model. Antimicrob Agents Chemother 53(2):412–420
Sparling PF (1983a) Bacterial virulence and pathogenesis: an overview. Rev Infect Dis 5(Suppl 4):S637–S646
Sparling GP (1983b) Estimation of microbial biomass and activity in soil using microcalorimetry. J Soil Sci 34(2):381–390
Surber J (2009) Efficacy and safety of torezolid phosphate (torezolid) in a dose-ranging phase 2 randomized, double-blind study in patients with severe complicated skin and skin structure infections (cSSSI). In: Abstracts of papers of 49th Interscience Conference on Antimicrob Agents Chemother, San Francisco, 2009
Tenover FC, McGowan JE Jr (1996) Reasons for the emergence of antibiotic resistance. Am J Med Sci 311(1):9–16
Tiberi S, Payen MC, Manika K, Ladeira I, Gonzalez Sanz M, Muñoz-Torrico M et al (2018) Clinical cases. In: Migliori GB, Bothamley G, Duarte R (eds) Tuberculosis (ERS monograph). European Respiratory Society, Sheffield, pp 381–398
Wilson ME (1995) Travel and the emergence of infectious diseases. Emerg Infect Dis 1(2):39
Ylikoski J, Savolainen S, Jousimies-Somer H (1989) Bacterial flora in the nasopharynx and nasal cavity of healthy young men. ORL 51(1):50–55
Zhanel GG, Cheung D, Adam H, Zelenitsky S, Golden A, Schweizer F, Gorityala B, Lagace-Wiens PR, Walkty A, Gin AS, Hoban DJ, Karlowsky JA (2016) Review of eravacycline, a novel fluorocycline antibacterial agent. Drugs 76(5):567–588
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Sagar, S., Kaistha, S., Das, A.J., Kumar, R. (2019). Advance Class of Antibiotics of the Twenty-First Century. In: Antibiotic Resistant Bacteria: A Challenge to Modern Medicine. Springer, Singapore. https://doi.org/10.1007/978-981-13-9879-7_3
Download citation
DOI: https://doi.org/10.1007/978-981-13-9879-7_3
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-9878-0
Online ISBN: 978-981-13-9879-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)